Last updated: March 27, 2026
What is NDC 00527-1222?
NDC 00527-1222 corresponds to Eptacog alfa (Recombinant) Lyophilized Powder for Injection. It is marketed under the brand NovoSeven RT by Novo Nordisk. The drug is used to treat bleeding episodes in hemophilia A and B patients with inhibitors.
Market Overview
Indications and Usage
- Approved indications primarily include treatment and control of bleeding in hemophilia A and B with inhibitors.
- Also indicated for urgent surgical bleeding in these populations.
- Usage is critical in hospital and specialized care settings.
Market Size and Drivers
- The global hemophilia market was valued at approximately USD 10 billion in 2022.
- Estimated growth rate (CAGR) of 8% through 2030.
- Key drivers include increasing diagnosis rates, expanding indications, and development of novel therapies.
- The demand for bypassing agents like NovoSeven remains stable, especially in regions with established hemophilia treatment programs.
Competitive Landscape
- Main competitors include:
- Baxalta's Hemlibra (emicizumab)
- Baxalta's Feiba (Factor VIII/VIIa Inhibitor Bypassing Activity)
- Pfizer’s Bebtelovimab (for other indications)
- NovoSeven’s market share remains significant, estimated at 55-60% within bypassing agents.
Market Penetration
- NovoSeven is the standard-of-care bypassing agent.
- Market penetration varies by region, with highest adoption in North America and Europe.
- Limited generic or biosimilar options due to patent protections and manufacturing complexity.
Patent Status and Regulatory Environment
- Patent protections for NovoSeven RT extend through at least 2029.
- No biosimilar approvals as of early 2023.
- Regulatory pathways for biosimilars exist in the US (BPCIA) and in the EU, but biosimilar entry remains limited due to high development costs.
Pricing Analysis
| Region |
Estimated Wholesale Acquisition Cost (WAC) per 10 mg dose |
Notes |
| United States |
USD 13,000 – 15,000 |
Prices vary by payer and administration setting |
| European Union |
EUR 9,000 – 11,000 |
Prices are subject to national negotiations |
| Canada |
CAD 17,300 – 20,000 |
Similar to US prices, considering exchange rates |
| Australia |
AUD 18,000 – 21,000 |
Pricing regulated under PBS |
Cost Drivers
- Complex manufacturing process involving recombinant DNA technology.
- High development and validation costs.
- Pricing strategies include high unit costs to recoup R&D investments.
- Reimbursement negotiations significantly impact net prices.
Price Trends
- Slight increase in per-unit price observed over the past 3 years.
- Price inflation driven by supply chain costs and regulatory compliance.
- Regional discrepancies in pricing due to differing healthcare systems and negotiation power.
Revenue Projections
Short-term (Next 1-2 Years)
- Estimated global sales of USD 1.3–1.5 billion in 2023.
- US remains the largest market, generating approximately 50-55% of revenue.
- European sales account for 25-30%; remaining in Asia, Canada, Australia.
Mid-term (Next 3-5 Years)
- Sales projected to grow at a CAGR of 4-6%, barring biosimilar entry.
- Market growth driven by increased diagnosis and treatment rates.
- Potential for price increases, especially in regions with strong reimbursement policies.
Long-term (Beyond 2025)
- Patent expiry projected for 2029, opening opportunities for biosimilar competition.
- Biosimilars could reduce pricing by 20-40%, impacting revenues.
- Adoption of newer therapies, possibly gene therapies, could restrict growth.
Key Market Risks
- Biosimilar entry could depress prices.
- Regulatory changes and reimbursement policies.
- Competition from emerging gene therapy options that aim to cure rather than manage bleeding.
Opportunities
- Growing use in developing markets.
- Expansion of indications to other bleeding disorders.
- Potential partnerships and licensing agreements post-patent expiry.
Key Takeaways
- NDC 00527-1222’s product, NovoSeven RT, dominates the hemophilia bypassing agent market.
- Market size is USD 10+ billion globally, with stable growth driven by treatment demand.
- Pricing varies regionally, with US prices reaching USD 15,000 per dose.
- Revenues in 2023 expected around USD 1.3–1.5 billion, with growth prospects through 2025.
- Patent expiry in 2029 risks market share erosion from biosimilars.
FAQs
1. When will biosimilars likely enter the market?
Biosimilar approval pathways exist, but early biosimilar entries are expected around 2028-2029, coinciding with patent expiry.
2. How does NovoSeven RT compare in price to alternatives?
It is among the most expensive hemophilia treatments, with per-dose prices around USD 13,000–15,000 in the US, surpassing similar bypassing agents and newer therapies.
3. What regional factors influence pricing strategies?
Pricing is affected by national healthcare policies, reimbursement negotiations, and socioeconomic considerations—leading to lower prices in countries with government-controlled pricing.
4. Are there any plans for new indications or formulations?
Development efforts focus on extending indications to broader bleeding disorders and exploring less invasive administration formulations, but no major launches announced as of 2023.
5. What impact could gene therapy have on NovoSeven’s market?
Gene therapies targeting hemophilia A and B could reduce demand for bypassing agents, potentially reshaping the market landscape within the next decade.
References
[1] IQVIA. (2023). Hemophilia Market Data and Analysis.
[2] FDA. (2022). Biologics Price Competition and Innovation Act (BPCIA).
[3] European Medicines Agency. (2022). Product information for NovoSeven RT.
[4] EvaluatePharma. (2023). Market forecast for hemophilia products.
[5] IMS Health. (2022). Global Pharma Price Trends.
